DIABETES Breaking news! Rosiglitazone and cardiovascular risk

被引：10
|
作者：
Kaul, Sanjay [1 ]
Diamond, George A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA
来源：
NATURE REVIEWS CARDIOLOGY | 2010年 / 7卷 / 12期
关键词：
MYOCARDIAL-INFARCTION; HEART-FAILURE; DEATH;
D O I：
10.1038/nrcardio.2010.160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In the past 3 years, several studies have reignited the controversy regarding the cardiovascular risk associated with the use of rosiglitazone. Until a prospective, well-controlled, randomized clinical trial is performed to adjudicate the issue definitively, physicians should be free to exercise clinical judgment, and weigh the comparative risks and benefits of agents such as rosiglitazone on a case-by-case basis.
引用
收藏
页码：670 / 672
页数：4
相关论文
共 50 条
  • [31] EFFECTS OF PIOGLITAZONE AND ROSIGLITAZONE ON GLUCOSE AND THE CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS
    Lee, J. K.
    Lee, E. K.
    VALUE IN HEALTH, 2008, 11 (06) : A497 - A497
  • [32] Diabetes & cardiovascular risk
    Mayaudon, H
    Dupuy, O
    Bordier, L
    Bauduceau, B
    PRESSE MEDICALE, 2000, 29 (25): : 1397 - 1400
  • [33] Rosiglitazone: rosy news for a thiazolidinedione
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) : 265 - 268
  • [34] Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
    Diamond, George A.
    Bax, Leon
    Kaul, Sanjay
    ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) : 578 - 581
  • [35] Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings
    Jain, Rahul
    Mullins, C. Daniel
    Lee, Helen
    Wong, Winston
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2012, 8 (01): : 47 - 59
  • [36] Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone
    Monami, Matteo
    Marchionni, Niccolo
    Mannucci, Edoardo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 82 (01) : 48 - 57
  • [37] Cardiovascular effects of rosiglitazone
    Le Feuvre, C
    PRESSE MEDICALE, 2004, 33 (11): : 735 - 745
  • [38] The cardiovascular safety of rosiglitazone
    Ajjan, Ramzi A.
    Grant, Peter J.
    EXPERT OPINION ON DRUG SAFETY, 2008, 7 (04) : 367 - 376
  • [39] The effect of glipizide, metformin and rosiglitazone on nontraditional cardiovascular risk factors in newly diagnosed patients with type 2 diabetes mellitus
    Gupta, Rajesh K.
    Rehan, Harmeet S.
    Rohatagi, Anurag
    Bhatacharjee, Jayashree
    Chopra, Deepti
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2010, 30 (03) : 123 - 128
  • [40] Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus
    Kadoglou, Nikolaos P. E.
    Iliadis, Fotios
    Sailer, Nikolaos
    Athanasiadou, Zoi
    Vitta, Ioulia
    Kapelouzou, Alikistis
    Karayannacos, Panayotis E.
    Liapis, Christos D.
    Alevizos, Miltiadis
    Angelopoulou, Nikoletta
    Vrabas, Ioannis S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2010, 59 (04): : 599 - 607
12345